PE84799A1 - Metodos mejorados para el procesamiento de proteina c activada - Google Patents

Metodos mejorados para el procesamiento de proteina c activada

Info

Publication number
PE84799A1
PE84799A1 PE1998000311A PE00031198A PE84799A1 PE 84799 A1 PE84799 A1 PE 84799A1 PE 1998000311 A PE1998000311 A PE 1998000311A PE 00031198 A PE00031198 A PE 00031198A PE 84799 A1 PE84799 A1 PE 84799A1
Authority
PE
Peru
Prior art keywords
activated protein
protein
activated
processing
improved methods
Prior art date
Application number
PE1998000311A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Clayton Baker
Andrew David Carlson
Theodore Arsay Sheliga
Lihua Huang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE84799A1 publication Critical patent/PE84799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE1998000311A 1997-04-28 1998-04-24 Metodos mejorados para el procesamiento de proteina c activada PE84799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
PE84799A1 true PE84799A1 (es) 1999-09-16

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
PE1998000311A PE84799A1 (es) 1997-04-28 1998-04-24 Metodos mejorados para el procesamiento de proteina c activada
PE1998000309A PE86299A1 (es) 1997-04-28 1998-04-24 Formulaciones de proteina c activada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE1998000309A PE86299A1 (es) 1997-04-28 1998-04-24 Formulaciones de proteina c activada

Country Status (34)

Country Link
US (4) US6159468A (enExample)
EP (2) EP0875563A3 (enExample)
JP (2) JP4383546B2 (enExample)
KR (2) KR100450856B1 (enExample)
CN (2) CN1235638C (enExample)
AR (2) AR015598A1 (enExample)
AT (1) ATE285788T1 (enExample)
AU (2) AU743531B2 (enExample)
BR (2) BR9809292A (enExample)
CA (2) CA2287267C (enExample)
CO (2) CO4950523A1 (enExample)
CZ (1) CZ298429B6 (enExample)
DE (1) DE69828330T2 (enExample)
DK (1) DK0875252T3 (enExample)
EA (2) EA002149B1 (enExample)
EG (1) EG23685A (enExample)
ES (1) ES2234072T3 (enExample)
HU (2) HUP0003401A3 (enExample)
ID (2) ID23172A (enExample)
IL (2) IL132325A (enExample)
IN (2) IN183798B (enExample)
MY (2) MY120984A (enExample)
NO (2) NO995134L (enExample)
NZ (2) NZ337828A (enExample)
PE (2) PE84799A1 (enExample)
PL (2) PL195090B1 (enExample)
PT (1) PT875252E (enExample)
SI (1) SI0875252T1 (enExample)
SV (2) SV1998000050A (enExample)
TR (2) TR199902529T2 (enExample)
TW (2) TW585871B (enExample)
UA (2) UA55448C2 (enExample)
WO (2) WO1998048822A1 (enExample)
ZA (2) ZA983497B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
AU1477000A (en) * 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
IL142249A0 (en) * 1998-12-10 2002-03-10 Lilly Co Eli Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
CA2463655A1 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
JP2006504772A (ja) * 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
BRPI0508992A (pt) * 2004-03-17 2007-09-04 Chiron Corp tratamento de pneumonia severa pela administração de tfpi
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
PT2029740E (pt) * 2006-05-31 2012-07-06 Genzyme Corp Utilização de polissacáridos para promoção de actividade enzimática
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
JP5179521B2 (ja) * 2007-03-05 2013-04-10 カディラ・ヘルスケア・リミテッド ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
IN2014DN11181A (enExample) 2012-07-04 2015-10-02 Univ Sydney
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
WO2018017190A2 (en) 2016-06-01 2018-01-25 Baxalta Incorporated Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CN1254284A (zh) 2000-05-24
BR9809292A (pt) 2000-07-04
JP2001527543A (ja) 2001-12-25
PE86299A1 (es) 1999-09-17
IN187157B (enExample) 2002-02-16
MY120984A (en) 2005-12-30
BR9809304B1 (pt) 2011-02-08
US6395270B1 (en) 2002-05-28
WO1998048818A1 (en) 1998-11-05
HUP0003401A2 (hu) 2001-02-28
SV1998000051A (es) 1998-12-11
TW585871B (en) 2004-05-01
DE69828330D1 (de) 2005-02-03
EP0875252A3 (en) 2000-07-26
US6159468A (en) 2000-12-12
EG23685A (en) 2007-05-09
ID22933A (id) 1999-12-16
CA2287267A1 (en) 1998-11-05
EA199900980A1 (ru) 2000-04-24
AR015598A1 (es) 2001-05-16
CA2288143A1 (en) 1998-11-05
CN1235638C (zh) 2006-01-11
US6162629A (en) 2000-12-19
HUP0003401A3 (en) 2003-01-28
JP4383547B2 (ja) 2009-12-16
EP0875563A3 (en) 2000-08-02
AU740753B2 (en) 2001-11-15
CA2288143C (en) 2012-08-21
NZ500346A (en) 2001-08-31
KR100564189B1 (ko) 2006-03-27
ATE285788T1 (de) 2005-01-15
CO4950523A1 (es) 2000-09-01
NO995198D0 (no) 1999-10-25
UA73071C2 (en) 2005-06-15
AU743531B2 (en) 2002-01-31
NO995134D0 (no) 1999-10-21
AU740753C (en) 2002-10-10
TWI242443B (en) 2005-11-01
EA002149B1 (ru) 2001-12-24
PL336420A1 (en) 2000-06-19
AU7258998A (en) 1998-11-24
CA2287267C (en) 2006-08-15
CN1227025C (zh) 2005-11-16
ZA983496B (en) 1999-10-25
AR012010A1 (es) 2000-09-13
JP2001524111A (ja) 2001-11-27
CZ381099A3 (cs) 2000-03-15
MY118591A (en) 2004-12-31
PL195642B1 (pl) 2007-10-31
AU7161898A (en) 1998-11-24
US6436397B1 (en) 2002-08-20
EA004881B1 (ru) 2004-08-26
SV1998000050A (es) 1999-01-13
WO1998048822A1 (en) 1998-11-05
PT875252E (pt) 2005-03-31
ID23172A (id) 2000-03-23
HU224826B1 (en) 2006-02-28
HUP0100284A3 (en) 2003-08-28
CO4940438A1 (es) 2000-07-24
KR20010020325A (ko) 2001-03-15
PL336889A1 (en) 2000-07-17
HUP0100284A2 (hu) 2001-06-28
IN183798B (enExample) 2000-04-15
TR199902529T2 (xx) 2000-02-21
EA199900979A1 (ru) 2000-06-26
NO995198L (no) 1999-10-25
EP0875563A2 (en) 1998-11-04
EP0875252B1 (en) 2004-12-29
IL132325A0 (en) 2001-03-19
TR199902631T2 (xx) 2000-01-21
JP4383546B2 (ja) 2009-12-16
DK0875252T3 (da) 2005-04-25
IL132502A0 (en) 2001-03-19
BR9809304A (pt) 2000-10-17
HK1016472A1 (en) 1999-11-05
IL132325A (en) 2005-07-25
NO995134L (no) 1999-12-21
CZ298429B6 (cs) 2007-10-03
ES2234072T3 (es) 2005-06-16
UA55448C2 (uk) 2003-04-15
EP0875252A2 (en) 1998-11-04
CN1261280A (zh) 2000-07-26
KR100450856B1 (ko) 2004-10-02
ZA983497B (en) 1999-10-25
NZ337828A (en) 2001-06-29
SI0875252T1 (en) 2005-06-30
PL195090B1 (pl) 2007-08-31
KR20010020242A (ko) 2001-03-15
DE69828330T2 (de) 2005-10-13

Similar Documents

Publication Publication Date Title
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
WO1996020688A3 (en) Triggered pore-forming agents
BR9407047A (pt) Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas
DE69806498D1 (de) Behandlung von kontaktlinsen mit wässrigen, alkalicarbonat-haltigen lösungen
ES2124461T3 (es) Derivados de oxalilamino-benzofurano y de benzotienilo.
ATE291917T1 (de) Topisch anzuwendende ketoconazol enthaltende emulsionen
BR0214907A (pt) Método para fluoração de um artigo poroso, artigo, e, aparelho para fluoração de um substrato
ES2022222B3 (es) Sistema desinfectante y limpiador para lentes de contacto
ATE194774T1 (de) Stabile, wässrige alpha-interferon lösungen
EA199901031A1 (ru) Производные бензимидазола
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
ATE19098T1 (de) Loesung zur behandlung von kontaktlinsen.
FI915093A0 (fi) Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning.
DK0378262T3 (da) Flydende detergentsammensætning indeholdende et enzym og et enzymstabiliseringssystem
TR26748A (tr) SU VE N-METIL-MORFOLIN-N-OKSIT ICINDE SELüLOZ CÖZELTISI.
DK1329461T3 (da) Fremgangsmåde til fjernelse af humane serum-albumin-polymerer
ES8304151A1 (es) "procedimiento para eliminar total o parcialmente acido aspartico y acido glutamico de hidrolizados proteicos o mezclas de aminoacidos".
ATE155883T1 (de) Kationselektive elektroden
KR880003211A (ko) 콘택트 렌즈의 처리 방법
ES2083576T3 (es) Procedimiento para la obtencion de una solucion de triformiato de aluminio que contiene metales alcalinos y/o alcalinoterreos, soluciones altamente concentradas de triformiato de aluminio que contienen metales alcalinos y/o alcalinoterreos y su empleo.
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
LU90993I2 (fr) Xigris-drotrécogine alfa(activée) et ses dérivés pharmaceutiquement acceptables
FR2754824B1 (fr) Nouvelle composition contenant du chitosan
DK401683A (da) Substituerede benzensulfonsyreestere, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
AR011178A1 (es) Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto

Legal Events

Date Code Title Description
FC Refusal